Merck & Co Deal Validates Complix's Cell-Penetrating Protein Scaffold Platform
This article was originally published in Scrip
Executive Summary
Complix, a private Belgian biotech company developing novel protein therapeutics, has secured Merck & Co Inc. as its first big name pharma partner. Complix will use its 'Alphabody' platform to deliver CPABs (cell-penetrating Alphabodies) against two undisclosed intracellular cancer targets suggested by Merck.